

Table 4.27

## Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2006-2010  
Females by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma <sup>d</sup>	71,958	99.7%	57,078	99.7%	7,346	99.6%	6,471	99.9%	205	100.0%	6,352	99.8%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	-	-	-	-	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> <sup>f</sup>	60,766	84.2%	47,669	83.3%	6,423	87.1%	5,861	90.5%	171	83.4%	5,405	84.9%
Cribiform carcinoma <i>in situ</i> (8201/2)	5,963	8.3%	4,606	8.0%	629	8.5%	619	9.6%	25	12.2%	562	8.8%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	4,485	6.2%	3,651	6.4%	371	5.0%	410	6.3%	-	-	366	5.8%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	23,138	32.1%	18,424	32.2%	2,486	33.7%	1,920	29.6%	65	31.7%	1,962	30.8%
Comedocarcinoma <i>in situ</i> (8501/2)	5,406	7.5%	4,268	7.5%	570	7.7%	493	7.6%	19	9.3%	488	7.7%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,206	1.7%	832	1.5%	211	2.9%	134	2.1%	-	-	121	1.9%
Noninfiltrating intracystic carcinoma(8504/2)	312	0.4%	208	0.4%	44	0.6%	55	0.8%	-	-	31	0.5%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,529	2.1%	1,227	2.1%	177	2.4%	108	1.7%	-	-	128	2.0%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	18,543	25.7%	14,306	25.0%	1,921	26.0%	2,101	32.4%	36	17.6%	1,728	27.2%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	8,296	11.5%	7,062	12.3%	650	8.8%	378	5.8%	23	11.2%	687	10.8%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	8,269	11.5%	7,039	12.3%	646	8.8%	378	5.8%	23	11.2%	687	10.8%
Lobular CIS <sup>f</sup> with other CIS <sup>f</sup> (8524/2)	26	0.0%	23	0.0%	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	2,430	3.4%	1,987	3.5%	229	3.1%	178	2.7%	-	-	218	3.4%
Other adenocarcinomas <sup>g</sup>	458	0.6%	352	0.6%	44	0.6%	54	0.8%	-	-	42	0.7%
Other <i>in situ</i> histologies <sup>h</sup>	188	0.3%	149	0.3%	29	0.4%	-	-	-	-	-	-
Total	72,146	100.0%	57,227	100.0%	7,375	100.0%	6,476	100.0%	205	100.0%	6,363	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

<sup>f</sup> Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

<sup>f</sup> CIS = Carcinoma *in situ*.

<sup>g</sup> Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

<sup>h</sup> Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.